Expression of CYLD and NF-kappaB in human cholesteatoma epithelium.
The tumor suppressor CYLD is a deubiquitinating enzyme that inhibits activation of the NF-kappaB, which has key roles in inflammation and apoptosis. We hypothesized that CYLD may regulate the NF-kappaB signaling pathway in cholesteatoma. We conducted immunohistochemistry to examine the expression of CYLD and NF-kappaB in 16 cases of cholesteatoma and paired cases of retroauricular (RA) skin. In cholesteatoma epithelium, activated NF-kappa B expression was significantly higher than in RA skin, whereas CYLD expression was significantly lower in cholesteatoma epithelium than in RA skin (P < .05). Furthermore, a significant inverse correlation was detected between CYLD and activated NF-kappaB expression in cholesteatoma epithelium (r = -0.630). We found that CYLD reduced and activated increased NF-kappaB in cholesteatoma epithelium in comparison to RA skin. The inverse correlation between CYLD and activated NF-kappaB in cholesteatoma may be involved in cholesteatoma epithelial hyperplasia.
Byun
Jae Yong
JY
Department of Otolaryngology, School of Medicine, Kyung Hee University, Seoul, South Korea. otorhino512@naver.com
Yune
Tae Young
TY
Lee
Jee Youn
JY
Yeo
Seung Geun
SG
Park
Moon Suh
MS
D018424:Cholesteatoma, Middle Ear / Q000378:metabolism* / Q000473:pathology; D000074749:Deubiquitinating Enzyme CYLD; D004848:Epithelium / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D016328:NF-kappa B / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
D016328:NF-kappa B; D025521:Tumor Suppressor Proteins; C409984:CYLD protein, human; D000074749:Deubiquitinating Enzyme CYLD